| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
180,310,000 |
| Market
Cap: |
41.24(B) |
| Last
Volume: |
799,597 |
Avg
Vol: |
866,609 |
| 52
Week Range: |
$191.51 - $228.9 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Seagen is a biotechnology company that develops and commercializes targeted therapies to treat cancer. Co. is commercializing ADCETRIS®, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas, PADCEV®, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, TIVDAK™, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers, and TUKYSA®, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. Co. is also developing a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
55,541 |
496,602 |
| Total Sell Value |
$0 |
$0 |
$11,412,520 |
$89,768,813 |
| Total People Sold |
0 |
0 |
7 |
8 |
| Total Sell Transactions |
0 |
0 |
19 |
72 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Simpson Todd E |
Chief Financial Officer |
• – – |
2020-08-18 |
4 |
AS |
$158.17 |
$1,464,959 |
D/D |
(9,262) |
142,554 |
|
17% |
|
| Liu Jean I |
GC/EVP, Leg Affairs |
• – – |
2020-08-18 |
4 |
AS |
$158.17 |
$1,082,823 |
D/D |
(6,846) |
63,946 |
|
17% |
|
| Love Ted W |
Director |
– • – |
2020-08-17 |
4 |
A |
$0.00 |
$0 |
D/D |
1,799 |
1,799 |
|
- |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2020-08-17 |
4 |
A |
$0.00 |
$0 |
D/D |
6,596 |
198,468 |
|
- |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2020-08-17 |
4 |
A |
$0.00 |
$0 |
D/D |
8,635 |
151,816 |
|
- |
|
| Dansey Roger D |
Chief Medical Officer |
• – – |
2020-08-17 |
4 |
AS |
$157.79 |
$71,006 |
D/D |
(450) |
122,493 |
|
15% |
|
| Dansey Roger D |
Chief Medical Officer |
• – – |
2020-08-17 |
4 |
A |
$0.00 |
$0 |
D/D |
13,192 |
122,943 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2020-08-17 |
4 |
A |
$0.00 |
$0 |
D/D |
27,982 |
746,321 |
|
- |
|
| Romp Charles R |
EVP, Commercial |
• – – |
2020-08-17 |
4 |
A |
$0.00 |
$0 |
D/D |
7,795 |
63,102 |
|
- |
|
| Liu Jean I |
GC/EVP, Legal Affairs |
• – – |
2020-08-17 |
4 |
A |
$0.00 |
$0 |
D/D |
7,195 |
70,792 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2020-08-10 |
4 |
AS |
$154.76 |
$4,463,263 |
D/D |
(28,475) |
718,339 |
|
25% |
|
| Siegall Clay B |
President and CEO |
• • – |
2020-08-10 |
4 |
OE |
$12.00 |
$341,700 |
D/D |
28,475 |
722,958 |
|
- |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2020-08-03 |
4 |
AS |
$164.96 |
$3,314,418 |
D/D |
(20,000) |
143,181 |
|
15% |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2020-07-17 |
4 |
AS |
$178.46 |
$1,435,363 |
D/D |
(8,000) |
191,840 |
|
-7% |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2020-07-17 |
4 |
OE |
$15.46 |
$123,680 |
D/D |
8,000 |
199,840 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2020-07-08 |
4 |
AS |
$172.55 |
$4,984,808 |
D/D |
(28,472) |
718,339 |
|
-1% |
|
| Siegall Clay B |
President and CEO |
• • – |
2020-07-08 |
4 |
OE |
$12.00 |
$341,664 |
D/D |
28,472 |
718,739 |
|
- |
|
| Romp Charles R |
EVP, Commercial |
• – – |
2020-07-02 |
4 |
AS |
$167.49 |
$119,253 |
D/D |
(712) |
55,307 |
|
-0% |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2020-07-01 |
4 |
AS |
$165.86 |
$1,939,352 |
D/D |
(11,573) |
163,181 |
|
2% |
|
| Liu Jean I |
GC/EVP, Leg Affairs |
• – – |
2020-06-19 |
4 |
AS |
$165.00 |
$1,629,705 |
D/D |
(9,877) |
63,597 |
|
-2% |
|
| Dansey Roger D |
Chief Medical Officer |
• – – |
2020-06-17 |
4 |
AS |
$157.74 |
$343,523 |
D/D |
(2,162) |
109,608 |
|
23% |
|
| Dansey Roger D |
Chief Medical Officer |
• – – |
2020-06-16 |
4 |
AS |
$157.15 |
$131,692 |
D/D |
(838) |
111,770 |
|
26% |
|
| Dansey Roger D |
Chief Medical Officer |
• – – |
2020-06-15 |
4 |
AS |
$157.15 |
$783,236 |
D/D |
(4,984) |
112,608 |
|
26% |
|
| Siegall Clay B |
President and CEO |
• • – |
2020-06-08 |
4 |
AS |
$145.03 |
$4,235,807 |
D/D |
(28,472) |
718,339 |
|
31% |
|
| Siegall Clay B |
President and CEO |
• • – |
2020-06-08 |
4 |
OE |
$12.00 |
$341,664 |
D/D |
28,472 |
721,039 |
|
- |
|
1805 Records found
|
|
Page 15 of 73 |
|
|
